{"article_title": "Epilepsy meets the crowd with healthcare crowdfunder PoliwoggMedCity News", "article_keywords": ["meets", "million", "help", "crowd", "foundation", "crowdfunding", "companies", "epilepsy", "crowdfunder", "poliwogg", "simon", "venture", "poliwoggmedcity", "healthcare", "investments"], "article_url": "http://medcitynews.com/2014/01/epilepsy-poliwogg-crowdfunding-in-healthcare/", "article_text": "New epilepsy treatments plus solutions for certain genetic liver and lung ailments will test the power of crowdfunding.\n\nNew York\u2019s Poliwogg will announce today at the JP Morgan Healthcare Conference that it has struck partnerships with the Epilepsy Foundation and Alpha 1 Foundation. Both groups will leverage their connections, used primarily for nonprofit grants, to crowdfund some of the same innovations in for-profit, private crowdfunded investments. The foundations will get a first look at the deals, and companies funded through Poliwogg should expect investments between $1 million and $3 million. In some cases they could go as high as $10 million, Poliwogg officials said.\n\nIt\u2019s the first of several aggressive moves you\u2019ll hear this year from those focused on crowdfunding in healthcare. The likes of Poliwogg and MedStartr are eager to break the perception that crowdfunding, typically connected to funding Veronica Mars movies and trendy consumer goods, can consistently provide serious capital to traditional and capital-intensive medical breakthroughs.\n\nAdvertisement\n\nWarren Lammert, chairman of the Epilepsy Foundation\u2019s board of directors and the co-founder of the Epilepsy Therapy Project, said crowdfunding is a \u201cnatural follow-on to support young companies\u201d beyond the grants and other support the organization provides.\n\n\u201cWe absolutely hope and intend to help bring more innovation, more effective new therapies forward to people living with seizures and epilepsy,\u201d said Lammert, whose organizations have also experimented with crowdfunding platforms including Indiegogo.\n\nLammert will circulate Poliwogg crowdfunding opportunities through its newsletters, websites and social media to tell its members about the opportunities. He expects investments from his Poliwogg initiatives to range between $1 million and $3 million.\n\nPoliwogg CEO Greg Simon said investments will complement grants, give donors a chance to continue supporting key projects and push companies through the \u201cvalley of death\u201d \u2013 allowing them to complete proofs of concept and other testing that make them more likely to receive larger, venture capital investments.\n\nVenture capitalists will get behind this concept because crowdfunding like this will help \u201cstock its pond\u201d with more quality companies, Simon said. He added that crowdfunding will not siphon off donor money of a foundation.\n\n\u201cIt will energize the donor base,\u201d Simon said, adding that Poliwogg partners will get a first look at these deals.\n\n\u201cPhilanthropy begins these companies but it won\u2019t sustain them,\u201d he said.\n\nThe Alpha 1 Foundation, meanwhile, will pair Poliwogg investments with investments it makes through TAP, its for-profit investment subsidiary, said John Walsh, president and CEO of the Alpha 1 Foundation. Walsh\u2019s group supports treatments for ailments related to Alpha-1 Antitrypsin Deficiency, a genetic condition that results in serious lung diseases in adults as well as liver disease.\n\n\u201cWe often will need co-investors, and see that Poliwogg may be such an investor,\u201d Walsh said.\n\nFoundations would be a critical validator of the crowdfunding process. Consider that the Epilepsy Foundation has provided funding to about half of the 100 new drugs, devices and diagnostics under development. Though, while some foundations, like Alpha-1, have developed fundraising arms, others have explicitly stayed away from fundraising \u2013 some to the point that they keep investors in those sectors off of the board.\n\nEstablishing this approach as a bridge for grant-making organizations and their donors to walk across could help plug the gap left by venture funds, which have dwindled and moved upstream.\n\nPoliwogg will be busy in the coming month. It will also announce today that Dennis Purcell, a senior managing partner at Aisling Capital and a Poliwogg investor, will join the company as a special adviser to help find quality companies for Poliwogg\u2019s platform. Poliwogg will then make another, smaller announcement on Tuesday at JP Morgan.\n\nPoliwogg prefers to call itself a \u201cfinancial innovation firm\u201d because of its interest in new and diverse ways to fund medical innovations. Over the next few months, it will unveil a series of S&P-like indexes for healthcare (its first, focused on the Affordable Care Act, is already available under the ticker symbol CARE). Poliwogg also hopes to launch publicly registered venture funds.\n\nSimon said Poliwogg will soon complete private investment of its own that is \u201cwell beyond $2 million\u201d but less than $5 million (the company has already secured $2.1 million, according to SEC filings).\n\n[Photo from Flickr user Catlinator]", "article_metadata": {"description": "New epilepsy treatments plus solutions for certain genetic liver and lung ailments will test the power of crowdfunding. New York\u2019s Poliwogg will announce today at the JP Morgan Healthcare Conference that it has struck partnerships with the Epilepsy Foundation and Alpha 1 Foundation. Both groups will leverage their connections, used primarily for nonprofit grants, to crowdfund some of the same innovations in for-profit, private crowdfunded investments. The foundations will get a first look at the deals, and companies funded through Poliwogg should expect investments between $1 million and $3 million. In some cases they could go as high as $10 million, Poliwogg officials said. It\u2019s the first of several aggressive moves you\u2019ll hear this year from those focused on crowdfunding in healthcare. The likes of Poliwogg and MedStartr are eager to break the perception that crowdfunding, typically connected to funding Veronica Mars movies and trendy consumer goods, can consistently provide serious capital to traditional and capital-intensive medical breakthroughs. Warren Lammert, chairman of the Epilepsy Foundation\u2019s board of directors and the co-founder of the Epilepsy Therapy Project, said crowdfunding is a \u201cnatural follow-on to support young companies\u201d beyond the grants and other support the organization provides. \u201cWe absolutely hope and intend to help bring more innovation, more effective new therapies forward to people living with seizures and epilepsy,\u201d said Lammert, whose organizations have also experimented with crowdfunding platforms including Indiegogo. Lammert will circulate Poliwogg crowdfunding opportunities through its newsletters, websites and social media to tell its members about the opportunities. He expects investments from his Poliwogg initiatives to range between $1 million and $3 million. Poliwogg CEO Greg Simon said investments will complement grants, give donors a chance to continue supporting key projects and push companies through the \u201cvalley of death\u201d \u2013 allowing them to complete proofs of concept and other testing that make them more likely to receive larger, venture capital investments. Venture capitalists will get behind this concept because crowdfunding like this will help \u201cstock its pond\u201d with more quality companies, Simon said. He added that crowdfunding will not siphon off donor money of a foundation. \u201cIt will energize the donor base,\u201d Simon said, adding that Poliwogg partners will get a first look at these deals. \u201cPhilanthropy begins these companies but it won\u2019t sustain them,\u201d he said. The Alpha 1 Foundation, meanwhile, will pair Poliwogg investments with investments it makes through TAP, its for-profit investment subsidiary, said John Walsh, president and CEO of the Alpha 1 Foundation. Walsh\u2019s group supports treatments for ailments related to Alpha-1 Antitrypsin Deficiency, a genetic condition that results in serious lung diseases in adults as well as liver disease. \u201cWe often will need co-investors, and see that Poliwogg may be such an investor,\u201d Walsh said. Foundations would be a critical validator of the crowdfunding process. Consider that the Epilepsy Foundation has provided funding to about half of the 100 new drugs, devices and diagnostics under development. Though, while some foundations, like Alpha-1, have developed fundraising arms, others have explicitly stayed away from fundraising \u2013 some to the point that they keep investors in those sectors off of the board. Establishing this approach as a bridge for grant-making organizations and their donors to walk across could help plug the gap left by venture funds, which have dwindled and moved upstream. Poliwogg will be busy in the coming month. It will also announce today that Dennis Purcell, a senior managing partner at Aisling Capital and a Poliwogg investor, will join the company as a special adviser to help find quality companies for Poliwogg\u2019s platform. Poliwogg will then make another, smaller announcement on Tuesday at JP Morgan. Poliwogg prefers to call itself a \u201cfinancial innovation firm\u201d because of its interest in new and diverse ways to fund medical innovations. Over the next few months, it will unveil a series of S&P-like indexes for healthcare (its first, focused on the Affordable Care Act, is already available under the ticker symbol CARE). Poliwogg also hopes to launch publicly registered venture funds. Simon said Poliwogg will soon complete private investment of its own that is \u201cwell beyond $2 million\u201d but less than $5 million (the company has already secured $2.1 million, according to SEC filings). [Photo from Flickr user Catlinator]", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "New epilepsy treatments plus solutions for certain genetic liver and lung ailments will test the power of crowdfunding. New York\u2019s Poliwogg will announce today at the JP Morgan Healthcare Conference that it has struck partnerships with the Epilepsy Foundation and Alpha 1 Foundation. Both groups will leverage their connections, used primarily for nonprofit grants, to crowdfund some of the same innovations in for-profit, private crowdfunded investments. The foundations will get a first look at the deals, and companies funded through Poliwogg should expect investments between $1 million and $3 million. In some cases they could go as high as $10 million, Poliwogg officials said. It\u2019s the first of several aggressive moves you\u2019ll hear this year from those focused on crowdfunding in healthcare. The likes of Poliwogg and MedStartr are eager to break the perception that crowdfunding, typically connected to funding Veronica Mars movies and trendy consumer goods, can consistently provide serious capital to traditional and capital-intensive medical breakthroughs. Warren Lammert, chairman of the Epilepsy Foundation\u2019s board of directors and the co-founder of the Epilepsy Therapy Project, said crowdfunding is a \u201cnatural follow-on to support young companies\u201d beyond the grants and other support the organization provides. \u201cWe absolutely hope and intend to help bring more innovation, more effective new therapies forward to people living with seizures and epilepsy,\u201d said Lammert, whose organizations have also experimented with crowdfunding platforms including Indiegogo. Lammert will circulate Poliwogg crowdfunding opportunities through its newsletters, websites and social media to tell its members about the opportunities. He expects investments from his Poliwogg initiatives to range between $1 million and $3 million. Poliwogg CEO Greg Simon said investments will complement grants, give donors a chance to continue supporting key projects and push companies through the \u201cvalley of death\u201d \u2013 allowing them to complete proofs of concept and other testing that make them more likely to receive larger, venture capital investments. Venture capitalists will get behind this concept because crowdfunding like this will help \u201cstock its pond\u201d with more quality companies, Simon said. He added that crowdfunding will not siphon off donor money of a foundation. \u201cIt will energize the donor base,\u201d Simon said, adding that Poliwogg partners will get a first look at these deals. \u201cPhilanthropy begins these companies but it won\u2019t sustain them,\u201d he said. The Alpha 1 Foundation, meanwhile, will pair Poliwogg investments with investments it makes through TAP, its for-profit investment subsidiary, said John Walsh, president and CEO of the Alpha 1 Foundation. Walsh\u2019s group supports treatments for ailments related to Alpha-1 Antitrypsin Deficiency, a genetic condition that results in serious lung diseases in adults as well as liver disease. \u201cWe often will need co-investors, and see that Poliwogg may be such an investor,\u201d Walsh said. Foundations would be a critical validator of the crowdfunding process. Consider that the Epilepsy Foundation has provided funding to about half of the 100 new drugs, devices and diagnostics under development. Though, while some foundations, like Alpha-1, have developed fundraising arms, others have explicitly stayed away from fundraising \u2013 some to the point that they keep investors in those sectors off of the board. Establishing this approach as a bridge for grant-making organizations and their donors to walk across could help plug the gap left by venture funds, which have dwindled and moved upstream. Poliwogg will be busy in the coming month. It will also announce today that Dennis Purcell, a senior managing partner at Aisling Capital and a Poliwogg investor, will join the company as a special adviser to help find quality companies for Poliwogg\u2019s platform. Poliwogg will then make another, smaller announcement on Tuesday at JP Morgan. Poliwogg prefers to call itself a \u201cfinancial innovation firm\u201d because of its interest in new and diverse ways to fund medical innovations. Over the next few months, it will unveil a series of S&P-like indexes for healthcare (its first, focused on the Affordable Care Act, is already available under the ticker symbol CARE). Poliwogg also hopes to launch publicly registered venture funds. Simon said Poliwogg will soon complete private investment of its own that is \u201cwell beyond $2 million\u201d but less than $5 million (the company has already secured $2.1 million, according to SEC filings). [Photo from Flickr user Catlinator]", "title": "Epilepsy meets the crowd with healthcare crowdfunder Poliwogg", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/crowd2-588x277.jpg", "updated_time": "2014-01-13T11:06:20-04:00", "url": "http://medcitynews.com/2014/01/epilepsy-poliwogg-crowdfunding-in-healthcare/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/crowd2-588x277.jpg", "description": "New epilepsy treatments plus solutions for certain genetic liver and lung ailments will test the power of crowdfunding. New York\u2019s Poliwogg will announce today at the JP Morgan Healthcare Conference that it has struck partnerships with the Epilepsy Foundation and Alpha 1 Foundation. Both groups will leverage their connections, used primarily for nonprofit grants, to crowdfund some of the same innovations in for-profit, private crowdfunded investments. The foundations will get a first look at the deals, and companies funded through Poliwogg should expect investments between $1 million and $3 million. In some cases they could go as high as $10 million, Poliwogg officials said. It\u2019s the first of several aggressive moves you\u2019ll hear this year from those focused on crowdfunding in healthcare. The likes of Poliwogg and MedStartr are eager to break the perception that crowdfunding, typically connected to funding Veronica Mars movies and trendy consumer goods, can consistently provide serious capital to traditional and capital-intensive medical breakthroughs. Warren Lammert, chairman of the Epilepsy Foundation\u2019s board of directors and the co-founder of the Epilepsy Therapy Project, said crowdfunding is a \u201cnatural follow-on to support young companies\u201d beyond the grants and other support the organization provides. \u201cWe absolutely hope and intend to help bring more innovation, more effective new therapies forward to people living with seizures and epilepsy,\u201d said Lammert, whose organizations have also experimented with crowdfunding platforms including Indiegogo. Lammert will circulate Poliwogg crowdfunding opportunities through its newsletters, websites and social media to tell its members about the opportunities. He expects investments from his Poliwogg initiatives to range between $1 million and $3 million. Poliwogg CEO Greg Simon said investments will complement grants, give donors a chance to continue supporting key projects and push companies through the \u201cvalley of death\u201d \u2013 allowing them to complete proofs of concept and other testing that make them more likely to receive larger, venture capital investments. Venture capitalists will get behind this concept because crowdfunding like this will help \u201cstock its pond\u201d with more quality companies, Simon said. He added that crowdfunding will not siphon off donor money of a foundation. \u201cIt will energize the donor base,\u201d Simon said, adding that Poliwogg partners will get a first look at these deals. \u201cPhilanthropy begins these companies but it won\u2019t sustain them,\u201d he said. The Alpha 1 Foundation, meanwhile, will pair Poliwogg investments with investments it makes through TAP, its for-profit investment subsidiary, said John Walsh, president and CEO of the Alpha 1 Foundation. Walsh\u2019s group supports treatments for ailments related to Alpha-1 Antitrypsin Deficiency, a genetic condition that results in serious lung diseases in adults as well as liver disease. \u201cWe often will need co-investors, and see that Poliwogg may be such an investor,\u201d Walsh said. Foundations would be a critical validator of the crowdfunding process. Consider that the Epilepsy Foundation has provided funding to about half of the 100 new drugs, devices and diagnostics under development. Though, while some foundations, like Alpha-1, have developed fundraising arms, others have explicitly stayed away from fundraising \u2013 some to the point that they keep investors in those sectors off of the board. Establishing this approach as a bridge for grant-making organizations and their donors to walk across could help plug the gap left by venture funds, which have dwindled and moved upstream. Poliwogg will be busy in the coming month. It will also announce today that Dennis Purcell, a senior managing partner at Aisling Capital and a Poliwogg investor, will join the company as a special adviser to help find quality companies for Poliwogg\u2019s platform. Poliwogg will then make another, smaller announcement on Tuesday at JP Morgan. Poliwogg prefers to call itself a \u201cfinancial innovation firm\u201d because of its interest in new and diverse ways to fund medical innovations. Over the next few months, it will unveil a series of S&P-like indexes for healthcare (its first, focused on the Affordable Care Act, is already available under the ticker symbol CARE). Poliwogg also hopes to launch publicly registered venture funds. Simon said Poliwogg will soon complete private investment of its own that is \u201cwell beyond $2 million\u201d but less than $5 million (the company has already secured $2.1 million, according to SEC filings). [Photo from Flickr user Catlinator]", "card": "summary", "title": "Epilepsy meets the crowd with healthcare crowdfunder Poliwogg"}, "fb": {"app_id": 148725768475669}, "article": {"section": "Daily", "tag": "Startups", "published_time": "2014-01-13T09:00:45-04:00", "modified_time": "2014-01-13T11:06:20-04:00"}, "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,Crowdfunding, epilepsy treatment, medical devices, pharmaceuticals, Poliwogg, Startups, , MedCity News", "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fd7f7e\"", "article_summary": "Consider that the Epilepsy Foundation has provided funding to about half of the 100 new drugs, devices and diagnostics under development.\nNew York\u2019s Poliwogg will announce today at the JP Morgan Healthcare Conference that it has struck partnerships with the Epilepsy Foundation and Alpha 1 Foundation.\nLammert will circulate Poliwogg crowdfunding opportunities through its newsletters, websites and social media to tell its members about the opportunities.\nIn some cases they could go as high as $10 million, Poliwogg officials said.\nVenture capitalists will get behind this concept because crowdfunding like this will help \u201cstock its pond\u201d with more quality companies, Simon said."}